Previous 10 | Next 10 |
- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients - - Streng...
SELLAS Life Sciences (NASDAQ: SLS ) +6% in premarket, as the the French regulatory authority has signed off Phase 3 REGAL study of galinpepimut-S (GPS) in patients with Acute Myeloid Leukemia (AML), who have achieved complete remission after second-line anti-le...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS ) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer ind...
SELLAS Life Sciences (NASDAQ: SLS ) : Q2 GAAP EPS of -$0.66 misses by $0.02 . Cash of $3.3M at end of Q2. The company raised $9.2M in gross proceeds in August. Press Release More news on: SELLAS Life Sciences Group, Inc., Earnings news and commentary, Healthcare stocks news, ,
- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market - - Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with multiple data readouts expected in next 18 months - NEW YORK, Aug. 13, 2020 (GLOBE NEWS...
Are Analysts Bullish On Penny Stocks? Penny stocks are riskier compared to blue-chip stocks . That’s inherently so, simply due to the facts of low prices, lower average liquidity, and higher speculation. Given that, however, traders look for penny stocks to buy every day. After Ko...
SELLAS Life Sciences ( SLS +24.6% ) will raise ~$9.2M, via private placement of up to 2.7M shares and warrants to purchase an aggregate of 2.7M shares, at a combined price of $3.335. More news on: SELLAS Life Sciences Group, Inc., Healthcare stocks news, , Stocks on the move, ...
NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indicati...
New York, New York--(Newsfile Corp. - June 23, 2020) - As the United States enters nearly its fifth month in the global fight against COVID-19, many investors have set their eyes on companies racing to discover a cure and restore things back to a sense of normalcy. But despite this new threat ...
NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view pre...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...